In a major push to combat the growing global threat of antimicrobial resistance (AMR), the Union Ministry of Health and Family Welfare has proposed bringing all antimicrobials under central regulatory oversight.
Issued via draft Gazette Notification G.S.R. 983 (E) dated November 6, the move seeks to amend the New Drugs and Clinical Trials (NDCT) Rules, 2019, by explicitly including ‘antimicrobials’ within the definition of a ‘New Drug’ under Rule 2(1)(w)(v).
The regulatory overhaul addresses mounting concerns that state authorities have been granting manufacturing licences for antimicrobial formulations without adequate scrutiny—specifically bypassing vital bioavailability, bioequivalence, and stability studies. Health officials warned that the absence of these assessments compromises drug quality, safety, and efficacy.
Substandard or ineffective medications not only endanger patients directly but also accelerate the emergence and spread of drug-resistant pathogens, an urgent issue previously highlighted in the G20 New Delhi Leaders’ Declaration under the ‘One Health’ framework.
Once the amendment is enacted, pharmaceutical manufacturers will be legally required to obtain prior permission from the Central Licensing Authority (CLA) before applying for a manufacturing licence from their respective State Licensing Authority (SLA).
The ministry has invited objections and suggestions from industry stakeholders and the general public within 30 days of the draft notification’s publication. Feedback can be sent to the Under Secretary (Drugs) at Kartavya Bhawan-1, New Delhi, or emailed to drugsdiv-mohfw@gov.in before finalisation.

















